Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Agricultural Inputs

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.

Revenue projections:

Revenue projections for BAYERCROP
Revenue projections for BAYERCROP

BAYERCROP's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 2.011000
forwardPE 27.970667
debtToEquity 3.687000
earningsGrowth 0.493000
revenueGrowth 0.322000
grossMargins 0.379030
operatingMargins 0.130450
trailingEps 126.530000
forwardEps 0.000000

Bayer CropScience Limited's current ratio of 2.011 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that Bayer CropScience Limited is financially well-prepared to meet its liabilities without difficulty.
BAYERCROP's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
With positive earnings and revenue growth, Bayer CropScience Limited is on a path to expand its business. This strong financial performance suggests the company will continue to grow, as increasing profits and revenue highlight a healthy outlook.

Price projections:

Price projections for BAYERCROP
Price projections for BAYERCROP

Having crossed above the higher end of projections, Bayer CropScience Limited's price indicates a successful upward trajectory. However, the limited room for further growth suggests that the stock may soon stabilize or correct, urging investors to exercise caution.

Recommendation changes over time:

Recommendations trend for BAYERCROP
Recommendations trend for BAYERCROP


Analysts' recent buy bias toward Bayer CropScience Limited suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see Bayer CropScience Limited as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.